Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

12
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
12
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

13
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
13
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

16
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2 Reinfection and Risk of Multisystem Inflammatory Syndrome in Children: A Case-Control Study.

The Pediatric infectious disease journal·2026
Same author

Further detail required to assess additional evidence on agreement between VITEK 2 and broth microdilution piperacillin/tazobactam testing in cephalosporin resistant Enterobacterales.

Journal of clinical microbiology·2026
Same author

Belimumab use in paediatric-onset systemic lupus erythematosus: a status report in France from a retrospective multicentre descriptive study.

Rheumatology (Oxford, England)·2026
Same author

Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Early and transient expansion of TCR Vβ21.3+ T cells in children with MIS-C: Clinical and longitudinal immunological characterization.

Joint bone spine·2026
Same author

Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases.

EBioMedicine·2026
Same journal

Severe Postoperative Hypernatremia in an Adolescent Following Sleeve Gastrectomy.

Pediatrics·2026
Same journal

Barriers to Implementing SMART for Asthma in Pediatric Primary Care.

Pediatrics·2026
Same journal

Blood Lead Testing Among Children Enrolled in Medicaid.

Pediatrics·2026
Same journal

From Screening to Support: Crafting Social Needs Response Systems That Work for Families.

Pediatrics·2026
Same journal

A Social Care Intervention in Pediatric Practices: A Stepped Wedge Cluster Trial.

Pediatrics·2026
Same journal

Pediatric Cheerleading-Related Head Injuries and the "Double Down" Rule Change.

Pediatrics·2026
See all related articles

Related Experiment Video

Updated: Jul 25, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.8K

Immunomodulatory Therapy for MIS-C.

Naïm Ouldali1,2,3, Mary Beth F Son4,5, Andrew J McArdle6

  • 1Division of Infectious diseases, Department of Pediatric Infectious Diseases, Sainte Justine University Hospital, University of Montreal, Quebec, Canada.

Pediatrics
|June 28, 2023
PubMed
Summary
This summary is machine-generated.

The combination of intravenous immunoglobulin (IVIG) and glucocorticoids improved cardiovascular dysfunction in children with multisystem inflammatory syndrome (MIS-C) compared to IVIG alone. Glucocorticoids alone did not show improved outcomes.

More Related Videos

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

450
Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
07:13

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

18.5K

Related Experiment Videos

Last Updated: Jul 25, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.8K
Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

450
Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
07:13

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

18.5K

Area of Science:

  • Pediatric critical care medicine
  • Immunology
  • Infectious diseases

Background:

  • Multisystem inflammatory syndrome in children (MIS-C) treatment strategies have conflicting evidence.
  • Optimal initial therapy for MIS-C remains an area of active research.

Conclusions:

  • The combination of IVIG and glucocorticoids demonstrated improved cardiovascular outcomes in MIS-C patients compared to IVIG monotherapy.
  • Glucocorticoids as a sole initial therapy for MIS-C did not show superior cardiovascular benefits.
  • The nonrandomized nature of the included studies is a key limitation.